STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-100)	SABATOLIMAB
PRONUNCIATION	sa" ba toe' li mab
THERAPEUTIC CLAIM	Antineoplastic, immunomodulator

CHEMICAL NAMES

1. Immunoglobulin G4 [226-proline,de-C-terminal-lysine], anti-(human hepatitis virus A cellular receptor 2) (human-*Mus musculus* monoclonal clone NVS260714 γ4-chain), disulfide with human-*Mus musculus* monoclonal clone NVS260714 κ-chain, dimer (Source: CAS)

2. Immunoglobulin G4-kappa, anti-[*Homo sapiens* HAVCR2 (hepatitis A virus cellular receptor 2, T-cell immunoglobulin mucin family member 3, Tim-3, TIM3, TIMD3, CD366)], humanized monoclonal antibody; gamma4 heavy chain humanized (1-444) [VH (*Homo sapiens* IGHV1-46*01 (87.8%) -(IGHD) -IGHJ4*01 (92.3%)) CDR-IMGT [8.8.11] (26-33.51-58.97-107) (1-118) -*Homo sapiens* IGHG4*01, G4v5 h P10 (CH1 (119-216), hinge 1-12 S10>P (226) (217-228), CH2 (229-338), CH3 (339-443), CHS K>del (444)) (119-444)], (132-218')-disulfide with kappa light chain humanized (1'-218') [V-KAPPA (*Homo sapiens* IGKV1-39*01 (81.6%) -IGKJ4*01 (100%)) CDR-IMGT [10.3.9] (27-36.54-56.93-101) (1'-111') -*Homo sapiens* IGKC*01 (100%), Km3 A45.1 (157), V101 (195) (112’-218’)]; dimer (224-224":227-227")-bisdisulfide; produced in Chinese hamster ovary (CHO) cells, glycoform alfa (Source: WHO pINN list 122)

STRUCTURAL FORMULA

Heavy chain

QVQLVQSGAE	VKKPGSSVKV	SCKASGYTFT	SYNMHWVRQA	PGQGLEWMGD	50
IYPGNGDTSY	NQKFKGRVTI	TADKSTSTVY	MELSSLRSED	TAVYYCARVG	100
GAFPMDYWGQ	GTTVTVSSAS	TKGPSVFPLA	PCSRSTSEST	AALGCLVKDY	150
FPEPVTVSWN	SGALTSGVHT	FPAVLQSSGL	YSLSSVVTVP	SSSLGTKTYT	200
CNVDHKPSNT	KVDKRVESKY	GPPCPPCPAP	EFLGGPSVFL	FPPKPKDTLM	250
ISRTPEVTCV	VVDVSQEDPE	VQFNWYVDGV	EVHNAKTKPR	EEQFNSTYRV	300
VSVLTVLHQD	WLNGKEYKCK	VSNKGLPSSI	EKTISKAKGQ	PREPQVYTLP	350
PSQEEMTKNQ	VSLTCLVKGF	YPSDIAVEWE	SNGQPENNYK	TTPPVLDSDG	400
SFFLYSRLTV	DKSRWQEGNV	FSCSVMHEAL	HNHYTQKSLS	LSLG	444

Light chain

AIQLTQSPSS	LSASVGDRVT	ITCRASESVE	YYGTSLMQWY	QQKPGKAPKL	50’
LIYAASNVES	GVPSRFSGSG	SGTDFTLTIS	SLQPEDFATY	FCQQSRKDPS	100’
TFGGGTKVEI	KRTVAAPSVF	IFPPSDEQLK	SGTASVVCLL	NNFYPREAKV	150’
QWKVDNALQS	GNSQESVTEQ	DSKDSTYSLS	STLTLSKADY	EKHKVYACEV	200’
THQGLSSPVT	KSFNRGEC				218’

Disulfide bridges

22-96	22’’-96’’	23’-92’	23’’’-92’’’	132-218’	132’’-218’’’	138’-198’	138’’’-198’’’
145-201	145’’-201’’	224-224’’	227-227’’	259-319	259’’-319’’	365-423	365’’-423’’

Glycosylation sites (N)

295 295’’

MOLECULAR FORMULA	$C_{6398}H_{9886}N_{1698}O_{2032}S_{48}$
MOLECULAR WEIGHT	144.6 kDa
TRADEMARK	None as yet
SPONSOR	Novartis Pharma AG
CODE DESIGNATIONS	NVP-MBG453; MBG453
CAS REGISTRY NUMBER	2252262-24-9
UNII	3L7R886Y06
WHO NUMBER	11256

gbk